Free lookups: 0/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
0 of 3 free lookups remaining Upgrade
New search Medicine profile Silver Sulphadiazine / Chlorhexine Gluconate

Clinical medicine profile

Silver Sulphadiazine / Chlorhexine Gluconate

Therapeutic agent (verify pharmacological class)

POM
Evidence state General guidance Reviewed 14 Aug 2026
Route
See product SmPC
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • [Silver Sulphadiazine] [Silver Sulphadiazine] Hypersensitivity to the active substance or excipients.
  • Additional absolute contraindications are indication- and product-specific — consult SmPC. [Chlorhexidine Gluconate] Hypersensitivity to the active substance or excipients.
  • Additional absolute contraindications are indication- and product-specific — consult SmPC.

Precautions

  • [From component Silver Sulphadiazine] Adequate fluid intake, monitor electrolyte balance
  • systemic S/E of sulphadiazine if applied over the large area.
  • Contraindications
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.

Paediatric

Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.

Renal

Review renal impairment dosing; many agents need CrCl/eGFR adjustment.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.

03 Clinical use

Use, effects & interactions

Indications

  • Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)).
  • Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
  • Burns, bacterial infections

Adverse effects

  • Adverse reactions vary by agent.
  • Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes).
  • Report suspected ADRs via national pharmacovigilance channels.
  • Fixed-dose/multi-ingredient product.
  • Clinical details partially inherited from component monographs: Silver Sulphadiazine.
  • Confirm combination SmPC for exact dosing.
04 Pharmacology

Mechanism & disposition

Combination product.

Combination product.Component mechanism (Silver Sulphadiazine)…bactericidal against both Gram +ve and -ve…
Read complete mechanism

Combination product. Component mechanism (Silver Sulphadiazine): Binds to cell membranes; bactericidal against both Gram +ve and -ve Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.

Onset

Product-specific

Duration

Product-specific

Route

See product SmPC

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

[Silver Sulphadiazine] [Silver Sulphadiazine] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Chlorhexidine Gluconate] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

[Silver Sulphadiazine] [Silver Sulphadiazine] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Chlorhexidine Gluconate] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; RxNorm (NLM RxNav); PubChem; Component monographs (multi-source pipeline)
Last reviewed14 Aug 2026
EvidenceGeneral guidance
Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.